✦ LIBER ✦

A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia

✍ Scribed by Gary Schiller; James Gajewski; Stephen Nimer; Mary Territo; Winston Ho; Myung Lee; Richard Champlin

Book ID: 114712993
Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 560 KB
Volume: 81
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.1992.tb08203.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized trial of two schedules of low

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

✍ Sergio Amadori; Stefan Suciu; Dominik Selleslag; Roberto Stasi; Giuliana Alimena 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

A randomized trial of liposomal daunorub

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

✍ Jorge Cortes; Hagop Kantarjian; Maher Albitar; Deborah Thomas; Stefan Faderl; Ch 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

## Abstract ## BACKGROUND Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti‐angiogenic activity, this study was designed to investigate the potential role of Th in t